STOCK TITAN

Bicycle Therapeutics plc American Depositary Shares - BCYC STOCK NEWS

Welcome to our dedicated page for Bicycle Therapeutics plc American Depositary Shares news (Ticker: BCYC), a resource for investors and traders seeking the latest updates and insights on Bicycle Therapeutics plc American Depositary Shares stock.

Bicycle Therapeutics plc (symbol: BCYC) is a pioneering clinical-stage biotechnology company with a mission to transform the pharmaceutical industry through its innovative Bicycle® product platform. This revolutionary platform focuses on developing a new class of medicines known as Bicycles, which are synthetic short peptides constrained to form two loops. These loops stabilize their structural geometry, granting them superior targeting abilities and efficiency compared to existing drug conjugate modalities.

The core business of Bicycle Therapeutics centers around creating transformational new therapies to enhance treatment options in oncology and other serious diseases. The company’s leading product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) designed to maximize tumor penetration while minimizing adverse effects on healthy tissues. Bicycles combine the beneficial properties of multiple therapeutic entities in a single modality – showcasing the affinity and selective pharmacology typical of antibodies, the rapid distribution kinetics of small molecules, and the adjustable pharmacokinetic half-life of peptides.

Bicycle Therapeutics is committed to addressing high unmet medical needs, particularly in oncology. Their proprietary IP is grounded in the groundbreaking work of scientific founders, and the company has made significant strides with their unique approach. Recent achievements include successful clinical trials and strategic partnerships aimed at advancing their robust pipeline of product candidates.

This innovative approach ensures that Bicycles exhibit a favorable safety profile and improved tolerability, making them a promising alternative to traditional therapies. As the company continues to evolve, it remains dedicated to enhancing patient outcomes and pioneering new treatment paradigms in the biotech space.

Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) announced that Genentech, part of the Roche Group, has exercised its second expansion option under a 2020 collaboration agreement, initiating a new program to develop Bicycle®-based immuno-oncology therapies. This move entails a $10 million payment to Bicycle, marking significant progress in their strategic partnership. The collaboration focuses on discovering and pre-clinically developing novel therapeutics targeting multiple cancer types. Both companies are optimistic about the potential of Bicycle technology in advancing cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.45%
Tags
none
-
Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) announced the dosing of the first patient in the Phase I/II trial of BT5528, a second-generation Bicycle Toxin Conjugate designed to target EphA2. Following a successful Phase I dose escalation, the expansion phase aims to evaluate BT5528's clinical activity in various cancer types, administering a recommended Phase II dose of 6.5 mg/m2 biweekly. Initial data, including safety and anti-tumor activity, is anticipated to be released next quarter. The trial includes up to 56 patients in the initial cohorts.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
none
-
Rhea-AI Summary

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology firm focused on a unique class of therapeutics, will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on June 8, 2022, at 8:00 a.m. ET. Investors can access a live webcast on their official site, with an archived replay available for 90 days post-event. Bicycle is pioneering the development of 'Bicycles,' synthetic short peptides that offer high affinity and selectivity for targeted diseases. Current clinical trials include BT5528 and BT8009, targeting EphA2 and Nectin-4.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.63%
Tags
conferences
Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of a Trials in Progress poster for its Phase I/II clinical trial of BT7480 at the 2022 ASCO Annual Meeting in Chicago, IL, scheduled for June 5, 2022. BT7480 is a novel Bicycle TICA™ targeting Nectin-4 while agonizing CD137 in patients with advanced malignancies. The study aims to evaluate the therapeutic potential of BT7480 in addressing unmet medical needs in oncology. Additional details about the study will be available on their website following the presentation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.2%
Tags
conferences clinical trial
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.12%
Tags
none
-
Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) reported significant clinical progress in its oncology pipeline during Q1 2022, including promising interim data for the BT8009 Phase I clinical trial with a 50% overall response rate in patients with urothelial cancer. As of March 31, 2022, the company has $407.4 million in cash and equivalents, expected to fund operations through 2024. However, it reported a net loss of $27.6 million, or $(0.93) per share, compared to a loss of $16.2 million in Q1 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
Rhea-AI Summary

Egle Therapeutics SAS has appointed Pierre Legault as Chairman and board member, effective March 2022. With over 35 years of experience in the biotech sector, his leadership is anticipated to enhance Egle's efforts in developing novel immunotherapies targeting regulatory T cells (Tregs) for oncology and autoimmune diseases. Mr. Legault's previous roles include Director at Syndax Pharmaceuticals and Chairman at Bicycle Therapeutics (BCYC), positioning him well to accelerate Egle's strategic initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.58%
Tags
management
-
Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) announced interim Phase I results for BT8009, a second-generation BTC targeting Nectin-4, at the 2022 AACR Annual Meeting. The overall confirmed response rate was 50%, with one complete response among eight urothelial cancer patients at a 5.0mg/m² dosage. No dose-limiting toxicities were observed, and the tolerability profile remained favorable. Four of five responders are still on therapy after 24 weeks. The Phase I trial continues to explore additional dosing options. A conference call will provide further insights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.69%
Tags
-
Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of interim Phase I results for BT8009, targeting Nectin-4, at the 2022 American Association for Cancer Research Annual Meeting. The oral presentation titled BT8009-100 Phase I/II Study will be on April 10, 2022, at 4:05 PM CT, presented by Meredith McKean from the Sarah Cannon Research Institute. Following the presentation, the company will hold a conference call on April 11, 2022, at 8:30 AM ET to discuss the findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.54%
Tags
conferences clinical trial
Rhea-AI Summary

Bicycle Therapeutics (NASDAQ: BCYC) announced updated preclinical results demonstrating the efficacy of its Bicycle® technology as a novel antiviral therapy against SARS-CoV-2. Presented at the 2022 Microbiology Society Annual Meeting in Dublin, the data showed that Bicycles bind to various epitopes of the SARS-CoV-2 spike protein and exhibit potent activity in vitro and in vivo. The research has received funding from InnovateUK, and Bicycle is optimistic about the potential of these small molecules in combating COVID-19 variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.65%
Tags

FAQ

What is the current stock price of Bicycle Therapeutics plc American Depositary Shares (BCYC)?

The current stock price of Bicycle Therapeutics plc American Depositary Shares (BCYC) is $14.68 as of December 20, 2024.

What is the market cap of Bicycle Therapeutics plc American Depositary Shares (BCYC)?

The market cap of Bicycle Therapeutics plc American Depositary Shares (BCYC) is approximately 1.0B.

What is Bicycle Therapeutics plc?

Bicycle Therapeutics plc is a clinical-stage biotechnology company developing a novel class of medicines known as Bicycles, focusing on oncology and other serious diseases.

What are Bicycles in the context of Bicycle Therapeutics?

Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry, designed to have superior targeting abilities and efficiency.

What is the main focus of Bicycle Therapeutics' research and development?

The main focus of Bicycle Therapeutics' R&D is on developing transformational therapies for oncology, addressing high unmet medical needs.

What is BT1718?

BT1718 is a Bicycle Toxin Conjugate (BTC) and the lead product candidate of Bicycle Therapeutics, designed to penetrate tumors effectively while sparing healthy tissues.

What makes Bicycles different from traditional drug conjugates?

Bicycles combine the properties of antibodies, small molecules, and peptides to offer rapid tumor penetration, selective pharmacology, and an adjustable pharmacokinetic profile, enhancing their efficacy and tolerability.

What recent achievements has Bicycle Therapeutics made?

Recent achievements include successful clinical trials and strategic partnerships aimed at advancing their pipeline of product candidates.

How does Bicycle Therapeutics' technology improve patient outcomes?

Their technology aims to deliver highly targeted therapies with minimal side effects, improving the efficacy and safety of cancer treatments.

What is the significance of Bicycle Therapeutics' proprietary IP?

Their proprietary IP is based on groundbreaking scientific research, allowing them to develop unique and highly effective therapeutic modalities.

Who are the founders of Bicycle Therapeutics?

The proprietary IP and technology are based on the innovative work of scientific founders in the biotechnology field.

What is the strategic goal of Bicycle Therapeutics?

The strategic goal is to revolutionize oncology treatment through their Bicycle® product platform, creating highly effective and well-tolerated therapies for patients.

Bicycle Therapeutics plc American Depositary Shares

Nasdaq:BCYC

BCYC Rankings

BCYC Stock Data

1.04B
46.59M
1.3%
92.36%
5.1%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CAMBRIDGE